Key Points
- Marshall Urist sold 20,000 shares of Royalty Pharma on Dec. 26 at $39.32 for $786,400 and executed multiple other December sales, leaving him with 100,000 shares — a 16.67% reduction in his direct holdings.
- Quarterly results were mixed: EPS of $1.17 beat estimates of $1.11 while revenue of $609.3M missed forecasts of $765.0M; the stock trades around $39 with a $22.56B market cap and a 1‑year range of $25.18–$41.24.
- Dividends and analyst view: Royalty Pharma pays a $0.22 quarterly dividend ($0.88 annualized, ~2.3% yield) and carries a consensus "Moderate Buy" rating with a $45.60 target price.
Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 20,000 shares of the business's stock in a transaction on Friday, December 26th. The stock was sold at an average price of $39.32, for a total transaction of $786,400.00. Following the completion of the sale, the executive vice president directly owned 100,000 shares of the company's stock, valued at $3,932,000. This represents a 16.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Marshall Urist also recently made the following trade(s):
- On Friday, December 19th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $38.38, for a total value of $767,600.00.
- On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $38.32, for a total value of $766,400.00.
- On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total value of $913,526.10.
- On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total transaction of $714,174.30.
- On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The shares were sold at an average price of $39.93, for a total transaction of $931,686.69.
- On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.90, for a total transaction of $727,855.80.
Royalty Pharma Stock Down 0.4%
NASDAQ RPRX opened at $39.08 on Tuesday. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.48 and a quick ratio of 3.48. The stock has a market capitalization of $22.56 billion, a PE ratio of 29.61, a PEG ratio of 2.06 and a beta of 0.46. Royalty Pharma PLC has a 1 year low of $25.18 and a 1 year high of $41.24. The business's 50-day moving average is $38.71 and its 200 day moving average is $37.01.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 EPS for the quarter, beating analysts' consensus estimates of $1.11 by $0.06. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%.The business had revenue of $609.29 million during the quarter, compared to analyst estimates of $765.01 million. Sell-side analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current year.
Royalty Pharma Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 10th. Investors of record on Friday, November 14th were paid a $0.22 dividend. The ex-dividend date of this dividend was Friday, November 14th. This represents a $0.88 dividend on an annualized basis and a yield of 2.3%. Royalty Pharma's dividend payout ratio (DPR) is presently 66.67%.
Analysts Set New Price Targets
Several research analysts have commented on the stock. The Goldman Sachs Group started coverage on shares of Royalty Pharma in a report on Tuesday, September 30th. They issued a "buy" rating and a $42.00 price objective for the company. Wall Street Zen lowered shares of Royalty Pharma from a "strong-buy" rating to a "buy" rating in a report on Friday, November 28th. Leerink Partners set a $45.00 target price on Royalty Pharma in a report on Thursday, December 11th. Cowen reissued a "buy" rating on shares of Royalty Pharma in a research report on Thursday, December 11th. Finally, Weiss Ratings cut Royalty Pharma from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Saturday, October 25th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $45.60.
View Our Latest Research Report on Royalty Pharma
Hedge Funds Weigh In On Royalty Pharma
Large investors have recently made changes to their positions in the business. Nordea Investment Management AB grew its holdings in Royalty Pharma by 603.9% during the 2nd quarter. Nordea Investment Management AB now owns 655,995 shares of the biopharmaceutical company's stock valued at $23,701,000 after buying an additional 562,799 shares in the last quarter. Watchtower Advisors LP bought a new position in shares of Royalty Pharma during the 2nd quarter valued at approximately $3,603,000. Creative Planning boosted its position in shares of Royalty Pharma by 22.7% during the 2nd quarter. Creative Planning now owns 52,553 shares of the biopharmaceutical company's stock valued at $1,893,000 after acquiring an additional 9,718 shares during the last quarter. Cookson Peirce & Co. Inc. grew its holdings in shares of Royalty Pharma by 55.1% in the second quarter. Cookson Peirce & Co. Inc. now owns 34,263 shares of the biopharmaceutical company's stock valued at $1,234,000 after purchasing an additional 12,171 shares in the last quarter. Finally, Sierra Summit Advisors LLC bought a new stake in Royalty Pharma in the second quarter worth $698,000. 54.35% of the stock is currently owned by hedge funds and other institutional investors.
About Royalty Pharma
(
Get Free Report)
Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.
The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
